Silo Pharma stock soars after European patent approval

2026-04-07 23:34:19

Investing.com — Silo Pharma Inc (NASDAQ:SILO) shares jumped 43.5% on Tuesday. The company had previously announced that the European Patent Office had issued a Rule 71(3) notification, indicating its intention to grant the company a patent for its pressure-preventive therapy.

The approved claims cover methods of preventing stress-induced fear and depression-like behaviors using selected serotonin 4 (5-HT4) receptor agonists. The patent application is titled “Serotonin 4 receptor agonists’ prophylactic efficacy against stress,” and is exclusively licensed by Columbia University.

This developmental-stage biopharmaceutical company said that, once the patent is approved, it is expected to protect major European markets. Silo Pharma is evaluating unitary patent protection and key country validations to maximize its geographic coverage.

The approach targets pathways associated with stress resilience rather than symptom management, representing a preventive treatment strategy for stress-related disorders. The company focuses on developing new formulations and drug delivery systems for conventional therapies and psychedelic drug therapy.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.